Weekly Digest – December 2025 Weekly Digest – December 2025 05 December 2025: OBI-902 receives consecutive FDA Orphan Drug Designation indication expanded to gastric cancer including gastroesophageal junction adenocarcinoma OBI Pharma has received a major boost in its oncology pipeline, […]
Weekly Digest – December 2025 Weekly Digest – December 2025 10 December 2025: GSK’227, a B7-H3-targeted antibody-drug conjugate, granted Orphan Drug Designation in small-cell lung cancer by the US FDA GSK’s B7-H3–targeted antibody-drug conjugate, Risvutatug rezetecan (GSK’227), has gained fresh […]
Weekly Digest – December 2025 Weekly Digest – December 2025 09 December 2025: DESTINY-Ovarian01 Phase 3 Trial of ENHERTU initiated as first-line maintenance therapy in patients with HER2 expressing advanced ovarian cancer The DESTINY-Ovarian01 Phase 3 trial has reached a […]
Weekly Digest – December 2025 Weekly Digest – December 2025 11 December 2025: Biohaven presents clinical safety and efficacy data for BHV-1510, a next-generation Trop2 ADC in combination with cemiplimab at the 2025 ESMO Immuno-Oncology Congress Biohaven reported new clinical […]
Weekly Digest – December 2025 Weekly Digest – December 2025 05 December 2025: Korea BNC and ProAbtek jointly develop Albubody’s dual-target next-generation ADC anticancer drug Korea BNC and ProAbTech signed a joint R&D deal to develop dual-target ADCs powered by […]
Weekly Digest – December 2025 Weekly Digest – December 2025 10 December 2025: Oxford BioTherapeutics enters into a strategic collaboration with GSK to discover novel targets for antibody-based therapeutics for the treatment of cancer Oxford BioTherapeutics (OBT) and GSK have […]
